Clinical trials
Neoplasm Metastasis trials in China with unknown status
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
104 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 3 |
| 2010 | 2 |
| 2011 | 3 |
| 2012 | 1 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 7 |
| 2016 | 4 |
| 2017 | 9 |
| 2018 | 9 |
| 2019 | 10 |
| 2020 | 12 |
| 2021 | 13 |
| 2022 | 14 |
| 2023 | 7 |
| 2024 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 104 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Fudan University | 9 |
| Chinese PLA General Hospital | 7 |
| Sun Yat-sen University | 5 |
| Chinese Academy of Medical Sciences | 4 |
| Sixth Affiliated Hospital, Sun Yat-sen University | 4 |
| Chongqing Precision Biotech Co., Ltd | 3 |
| Jiangsu HengRui Medicine Co., Ltd. | 3 |
| Peking Union Medical College Hospital | 3 |
| Xu jianmin | 3 |
| Betta Pharmaceuticals Co., Ltd. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasm Metastasis | 104 |
| Recurrence | 16 |
| Colorectal Neoplasms | 15 |
| Neoplasms | 10 |
| Breast Neoplasms | 9 |
| Stomach Neoplasms | 7 |
| Nasopharyngeal Carcinoma | 6 |
| Liver Neoplasms | 5 |
| Pancreatic Neoplasms | 5 |
| Lymphoma | 4 |
Trials
Showing 1 to 25 of 104. Each trial links to its page on Pharma Observatory.
4 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.